Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection

Competing Interest Statement

MJP reports consulting for Gilead Sciences and AstraZeneca, outside the submitted work. DRW has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of the company, and also serves on its Board of Directors. Dr. Walt's interests were reviewed and are managed by Mass General Brigham and Harvard University in accordance with their conflict-of-interest policies.

Funding Statement

This work was supported by funding from the PolyBio Research Foundation to support the LIINC Clinical Core, as well as support from NIH/NIAID 3R01AI141003-03S1, NIH/NIAID R01AI158013, and NIH/NIAID K23AI134327.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the UCSF Institutional Review Board.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes